Sonoma Pharmaceuticals (STU:O8Z3) Additional Paid-In Capital : €185.96 Mil(As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Additional Paid-In Capital?

Sonoma Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2023 (€185.59 Mil) to Sep. 2023 (€188.53 Mil) but then stayed the same from Sep. 2023 (€188.53 Mil) to Dec. 2023 (€185.96 Mil).

Sonoma Pharmaceuticals's annual additional paid-in capital increased from Mar. 2021 (€158.94 Mil) to Mar. 2022 (€179.21 Mil) and increased from Mar. 2022 (€179.21 Mil) to Mar. 2023 (€187.64 Mil).

Sonoma Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Sonoma Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Additional Paid-In Capital Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

162.91

168.84

158.94

179.21

187.64

Sonoma Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															186.85	187.64	185.59	188.53	185.96

Sonoma Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sonoma Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines